Mar 24, 2026 | ImmunityBio's Third FDA Warning Letter; Gilead Bets $1.68B on Ouro Medicines Autoimmune Bispecifi... episode artwork

EPISODE · Mar 25, 2026 · 9 MIN

Mar 24, 2026 | ImmunityBio's Third FDA Warning Letter; Gilead Bets $1.68B on Ouro Medicines Autoimmune Bispecifi...

from The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus · host BZ Group

ImmunityBio stock crashes 21%+ after FDA names CEO andchairman in third ANKTIVA promotional warning letter in seven months. Gilead acquires Ouro Medicines for $1.68B upfront to build autoimmune bispecific franchise. UCB commits $2B to first U.S. biologics plant in Georgia.Visit us at: www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, ImmunityBio, IBRX, ANKTIVA, FDA warning letter, Gilead, Ouro Medicines, gamgertamig, BCMA CD3, bispecific antibody, autoimmune disease, UCB, Bimzelx, biologics manufacturing, Shionogi, Apnimed, Milestone Pharmaceuticals, etripamil, CARDAMYST, Rezolute,Karyopharm, Xpovio, MFN drug pricing, Eli Lilly, Ocugen, Lilly

ImmunityBio stock crashes 21%+ after FDA names CEO andchairman in third ANKTIVA promotional warning letter in seven months. Gilead acquires Ouro Medicines for $1.68B upfront to build autoimmune bispecific franchise. UCB commits $2B to first U.S. biologics plant in Georgia.Visit us at: www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, ImmunityBio, IBRX, ANKTIVA, FDA warning letter, Gilead, Ouro Medicines, gamgertamig, BCMA CD3, bispecific antibody, autoimmune disease, UCB, Bimzelx, biologics manufacturing, Shionogi, Apnimed, Milestone Pharmaceuticals, etripamil, CARDAMYST, Rezolute,Karyopharm, Xpovio, MFN drug pricing, Eli Lilly, Ocugen, Lilly

NOW PLAYING

Mar 24, 2026 | ImmunityBio's Third FDA Warning Letter; Gilead Bets $1.68B on Ouro Medicines Autoimmune Bispecifi...

0:00 9:23

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus?

This episode is 9 minutes long.

When was this The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus episode published?

This episode was published on March 25, 2026.

What is this episode about?

ImmunityBio stock crashes 21%+ after FDA names CEO andchairman in third ANKTIVA promotional warning letter in seven months. Gilead acquires Ouro Medicines for $1.68B upfront to build autoimmune bispecific franchise. UCB commits $2B to first U.S....

Can I download this The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!